Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of a Multimodal Strength and Dual-Task Program on Sarcopenia and Functional Performance in People With Parkinson's Disease and Parkinsonian Syndromes

NCT07907302 is registered in ClinicalTrials.gov with University of Valencia as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07907302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of a Multimodal Strength and Dual-Task Program on Sarcopenia and Functional Performance in People With Parkinson's Disease and Parkinsonian Syndromes
Lead sponsor
University of Valencia
Phase
Not applicable
Overall status
Recruiting
Start date
January 11, 2027
Completion date
December 31, 2031
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease (disorder), parkinsonism or parkinson's disease nos

Arms

As registered; 3 arms.

  • Education group Active comparatorNutricional Education and General Exercise Guidelines

    Participants will receive standardized nutritional education and general physical exercise guidelines through structured educational materials in a strucutred way throughout 12-weeks.

  • Progressive Resistance Training (PRT) ExperimentalProgressive Resistance Training With Cognitive Dual-Task Training

    Participants will receive standardized nutritional education and progressive resistance training combined with cognitive dual-task training by mean of two supervised physiotherapy sessions per week for 12 weeks.

  • Progressive Resistance Training + Inestability Group ExperimentalProgressive Resistance Training With Cognitive Dual-Task and Inestability Training

    Participants will receive standardized nutritional education and the same progressive resistance and cognitive dual-task training principles as the PRT Group, with the addition of instability and increased postural control demands, 2 sessions per week for 12 weeks.

Primary endpoints

Registered primary outcome measures; 8 primary.

  • Handgrip Strength Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2).

    Handgrip strength will be assessed using handgrip dynamometry as a measure of muscle strength within the EWGSOP2 sarcopenia assessment framework. Higher values indicate greater muscle strength.

  • Physical Performance - Short Physical Performance Battery (SPPB) Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2).

    Physical performance will be assessed using the Short Physical Performance Battery (SPPB), which evaluates balance, gait speed, and lower-limb functional performance. The total score ranges from 0 to 12 points, with higher scores indicating better physical performance.

  • Body Composition -Body fat (%) Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2).

    It will be assessed assessed using bioelectrical impedance analysis (BIA) , measured in %.

  • Body Composition -Body fat (kg) Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2).

    It will be assessed assessed using bioelectrical impedance analysis (BIA), measured in kg.

  • Body Composition -Lean mass (kg) Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2).

    It will be assessed assessed using bioelectrical impedance analysis (BIA) , measured in kg.

+3 more primary endpoints

Lead sponsor's other trials

University of Valencia, most recent start first.

Similar trials

Same condition (Sarcopenia) and phase, most recent start first.